[Use of preductal in therapy of hemodynamic complications in patients with tuberculosis].
To treat hemodynamic disorders, preductal was used in combination with antibacterial therapy in 30 patients with disseminated destructive pulmonary tuberculosis for a month. A control group comprising 31 patients was in parallel observed. Clinical, electrocardiographic, and echocardiographic studies were performed to evaluate the efficacy of preductal. The drug was found to promote improvements in left ventricular function and central hemodynamics as a decrease in end-systolic volume and increases in ejection fraction and stroke and minute volumes. Preductal exerted no significant effect on right ventricular dysfunction associated with chronic cor pulmonale.
Ditiatkov
A E
AE
Radzevich
A E
AE
Tikhonov
V A
VA
Sitnikova
N A
NA
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome; D014292:Trimetazidine / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016276:Ventricular Function / Q000187:drug effects* / Q000502:physiology
D000995:Antitubercular Agents; D014665:Vasodilator Agents; D014292:Trimetazidine